Qiu Lige, Li Hailiang, Fu Sirui, Chen Xiaofang, Lu Ligong
Department of Intervention, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, Guangdong 519000, P.R. China.
Department of Otolaryngology Head and Neck Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, P.R. China.
Oncol Lett. 2018 Feb;15(2):2039-2048. doi: 10.3892/ol.2017.7568. Epub 2017 Dec 8.
Liver cancer stem cells (LCSCs) have important roles in the occurrence, development, recurrence, therapy resistance and metastasis of hepatocellular carcinoma (HCC). Therefore, intensive studies are undergoing to identify the mechanisms by which LCSCs contribute to HCC invasion and metastasis, and to design more efficient treatments for this disease. With continuous efforts in LCSC research over the years, therapies targeting LCSCs are thought to have great potential for the clinical treatment and prognosis of liver cancer. Novel LCSC surface markers are continuously discovered and several have been used in targeted therapies to reduce HCC recurrence, metastasis, and drug resistance following tumor resection. The present review describes the surface markers characterizing LCSCs and the recent progress in therapies targeting these markers, including antibodies and polypeptides.
肝癌干细胞（LCSCs）在肝细胞癌（HCC）的发生、发展、复发、治疗抵抗及转移中发挥着重要作用。因此，目前正在进行深入研究，以确定LCSCs促进HCC侵袭和转移的机制，并设计针对该疾病更有效的治疗方法。多年来，随着LCSC研究的不断努力，针对LCSCs的治疗方法被认为在肝癌的临床治疗和预后方面具有巨大潜力。新型LCSC表面标志物不断被发现，其中一些已被用于靶向治疗，以降低肿瘤切除后HCC的复发、转移及耐药性。本综述描述了表征LCSCs的表面标志物以及针对这些标志物的治疗方法（包括抗体和多肽）的最新进展。
